0001213900-22-056376.txt : 20220916 0001213900-22-056376.hdr.sgml : 20220916 20220916090005 ACCESSION NUMBER: 0001213900-22-056376 CONFORMED SUBMISSION TYPE: 6-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220916 FILED AS OF DATE: 20220916 DATE AS OF CHANGE: 20220916 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NeuroSense Therapeutics Ltd. CENTRAL INDEX KEY: 0001875091 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: L3 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 6-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-41084 FILM NUMBER: 221247040 BUSINESS ADDRESS: STREET 1: 11 HAMENOFIM ST. STREET 2: BUILDING B CITY: HERZLIYA STATE: L3 ZIP: 4672562 BUSINESS PHONE: 972-9-9531142 MAIL ADDRESS: STREET 1: 11 HAMENOFIM ST. STREET 2: BUILDING B CITY: HERZLIYA STATE: L3 ZIP: 4672562 6-K 1 ea165875-6k_neurosense.htm REPORT OF FOREIGN PRIVATE ISSUER

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 6-K

 

Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16

Under the Securities Exchange Act of 1934

 

For the Month of September 2022

 

Commission File Number: 001-41084

 

NeuroSense Therapeutics Ltd.

(Translation of registrant’s name into English)

 

11 HaMenofim Street, Building B
Herzliya 4672562 Israel
+972-9-799-6183
(Address of principal executive office)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒     Form 40-F ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

 

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

 

 

 

 

 

 

NeuroSense Therapeutics reports publication of results from their Phase IIa ALS study with PrimeC in a peer-reviewed journal. The article titled: “Combination of ciprofloxacin/celecoxib as a novel therapeutic strategy for ALS,” was published in Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration.

 

https://www.tandfonline.com/doi/full/10.1080/21678421.2022.2119868

 

1

 

  

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

  NeuroSense Therapeutics Ltd.
     
Date: September 16, 2022 By: /s/ Alon Ben-Noon
    Alon Ben-Noon
    Chief Executive Officer

 

 

2